[go: up one dir, main page]

ECSP11010786A - 5-alquinil-pirimidinas - Google Patents

5-alquinil-pirimidinas

Info

Publication number
ECSP11010786A
ECSP11010786A EC2011010786A ECSP11010786A ECSP11010786A EC SP11010786 A ECSP11010786 A EC SP11010786A EC 2011010786 A EC2011010786 A EC 2011010786A EC SP11010786 A ECSP11010786 A EC SP11010786A EC SP11010786 A ECSP11010786 A EC SP11010786A
Authority
EC
Ecuador
Prior art keywords
alquinil
pyrimidins
medicine
excessive
prepare
Prior art date
Application number
EC2011010786A
Other languages
English (en)
Inventor
Tobias Wunberg
Der Veen Lars Anders Van
Ralph Brueckner
Oliver Kraemer
Darryl Mcconnell
Dirk Kessler
Siegfried Schneider
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40202900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11010786(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP11010786A publication Critical patent/ECSP11010786A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Laminated Bodies (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)

Abstract

La presente invención comprende compuestos de fórmula general (1)en la queR1 a R4 se definen como en la reivindicación 1, que son adecuados para el tratamiento adecuado de enfermedades caracterizadas por proliferación celular excesiva o anormal, y el uso de los mismos para preparar un medicamento que tiene las propiedades mencionadas anteriormente.
EC2011010786A 2008-07-29 2011-01-27 5-alquinil-pirimidinas ECSP11010786A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08161369 2008-07-29

Publications (1)

Publication Number Publication Date
ECSP11010786A true ECSP11010786A (es) 2011-02-28

Family

ID=40202900

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011010786A ECSP11010786A (es) 2008-07-29 2011-01-27 5-alquinil-pirimidinas

Country Status (25)

Country Link
US (1) US8916548B2 (es)
EP (1) EP2323992B1 (es)
JP (1) JP5599791B2 (es)
KR (1) KR20110041536A (es)
CN (1) CN102112450A (es)
AR (1) AR072845A1 (es)
AU (1) AU2009275957A1 (es)
BR (1) BRPI0916679A2 (es)
CA (1) CA2731909A1 (es)
CL (1) CL2011000195A1 (es)
CO (1) CO6341617A2 (es)
DK (1) DK2323992T3 (es)
EA (1) EA201100255A1 (es)
EC (1) ECSP11010786A (es)
ES (1) ES2597903T3 (es)
HU (1) HUE029837T2 (es)
IL (1) IL210343A0 (es)
MA (1) MA32505B1 (es)
MX (1) MX2011000729A (es)
NZ (1) NZ590558A (es)
PE (1) PE20110196A1 (es)
PL (1) PL2323992T3 (es)
TW (1) TW201010984A (es)
UY (1) UY32009A (es)
WO (1) WO2010012740A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2323992T3 (pl) 2008-07-29 2017-01-31 Boehringer Ingelheim International Gmbh 5-alkinylo-pirymidyny
NZ590560A (en) 2008-07-29 2012-12-21 Boehringer Ingelheim Int Indolinone Inhibitors of cell cycle kinases
AR076332A1 (es) 2009-04-21 2011-06-01 Boehringer Ingelheim Int Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.
UY33198A (es) * 2010-01-26 2011-08-31 Boehringer Ingelheim Int 5-alquinil-pirimidinas.
UY33199A (es) 2010-01-26 2011-08-31 Boehringer Ingelheim Int 5-alquinil-pirimidinas.
US8466162B2 (en) * 2011-01-26 2013-06-18 Boehringer Ingelheim International Gmbh 5-alkynyl-pyridines
TW201245176A (en) * 2011-01-26 2012-11-16 Boehringer Ingelheim Int New 5-alkynyl-pyridines
US8912200B2 (en) * 2011-07-28 2014-12-16 Nerviano Medical Sciences S.R.L. Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors
UA110995C2 (uk) * 2011-10-07 2016-03-10 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як модулятори метаботропного глутаматного рецептора
SMT202300014T1 (it) 2013-12-11 2023-05-12 Celgene Quanticel Research Inc Inibitori della demetilasi lisina-specifica-1
AU2015253040B2 (en) * 2014-05-01 2020-04-09 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
BR112017004334A2 (pt) * 2014-09-05 2018-08-07 Celgene Quanticel Res Inc inibidores de desmetilase específica de lisina-1.
CN104803921A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种苯取代嘧啶衍生物的制备方法
CN104744376A (zh) * 2015-03-14 2015-07-01 长沙深橙生物科技有限公司 一种2-异丙基嘧啶衍生物的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3832570A1 (de) * 1988-09-24 1990-03-29 Hoechst Ag 7-substituierte derivate der 3,5-dihydroxyhept-6-insaeure, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte
AU5704594A (en) 1992-12-18 1994-07-19 Wellcome Foundation Limited, The Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
US5622954A (en) 1994-05-11 1997-04-22 Fmc Corporation 5[W(substituted aryl)alkenylene and alkynylene]-2,4-diaminopyrimidines as pesticides
DE60110391T2 (de) 2000-02-25 2006-01-26 F. Hoffmann-La Roche Ag Adenosin-rezeptor modulatoren
EP1303495B1 (en) * 2000-07-24 2010-05-26 Krenitsky Pharmaceuticals, Inc. Substituted 5-alkynyl pyrimidines having neurotrophic activity
CA2528938A1 (en) * 2003-06-13 2005-02-24 Zentaris Gmbh Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof
US20080027076A1 (en) 2003-12-24 2008-01-31 Astrazeneca Ab Pyrimidines With Tie2 (Tek) Activity
RS55551B1 (sr) * 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
EP1846399A1 (en) 2005-02-01 2007-10-24 AstraZeneca AB Pyrimidine compounds having tie2 (tek) inhibitory activity
WO2006082373A1 (en) 2005-02-01 2006-08-10 Astrazeneca Ab Pyrimidine compounds having ties (tek) inhibitory activity
US20070135437A1 (en) 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
WO2006106721A1 (ja) 2005-03-30 2006-10-12 Shionogi & Co., Ltd. チロシンキナーゼ阻害作用を有するピリミジン誘導体
WO2006103449A2 (en) 2005-03-31 2006-10-05 Astrazeneca Ab Saminopyrimidine derivates with tie2 inhibiting activity
CN103819416A (zh) * 2005-10-07 2014-05-28 埃克塞里艾克西斯公司 N-(3-氨基-喹喔啉-2-基)-磺酰胺衍生物及其作为磷脂酰肌醇3-激酶抑制剂的用途
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EP2057129A1 (en) 2006-08-24 2009-05-13 AstraZeneca AB Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
BRPI0722079B8 (pt) 2006-12-29 2021-05-25 Janssen R & D Ireland pirimidinas 5,6-substituídas inibidoras de hiv e composição farmacêutica que as compreende
EP2022785A1 (en) 2007-06-20 2009-02-11 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines as Tie2 kinase inhibitors
PL2323992T3 (pl) 2008-07-29 2017-01-31 Boehringer Ingelheim International Gmbh 5-alkinylo-pirymidyny
UY33199A (es) 2010-01-26 2011-08-31 Boehringer Ingelheim Int 5-alquinil-pirimidinas.

Also Published As

Publication number Publication date
CL2011000195A1 (es) 2011-07-08
WO2010012740A1 (en) 2010-02-04
CN102112450A (zh) 2011-06-29
HUE029837T2 (en) 2017-04-28
US20110281838A1 (en) 2011-11-17
CA2731909A1 (en) 2010-02-04
PE20110196A1 (es) 2011-04-03
BRPI0916679A2 (pt) 2015-11-17
CO6341617A2 (es) 2011-11-21
IL210343A0 (en) 2011-03-31
EP2323992B1 (en) 2016-07-20
EA201100255A1 (ru) 2011-08-30
PL2323992T3 (pl) 2017-01-31
JP2011529468A (ja) 2011-12-08
MA32505B1 (fr) 2011-07-03
KR20110041536A (ko) 2011-04-21
UY32009A (es) 2010-02-26
US8916548B2 (en) 2014-12-23
JP5599791B2 (ja) 2014-10-01
AU2009275957A1 (en) 2010-02-04
MX2011000729A (es) 2011-03-15
NZ590558A (en) 2012-12-21
TW201010984A (en) 2010-03-16
AR072845A1 (es) 2010-09-22
ES2597903T3 (es) 2017-01-24
DK2323992T3 (en) 2016-10-31
EP2323992A1 (en) 2011-05-25

Similar Documents

Publication Publication Date Title
UY33199A (es) 5-alquinil-pirimidinas.
ECSP11010786A (es) 5-alquinil-pirimidinas
ECSP088932A (es) Nuevos compuestos químicos
ECSP099823A (es) Nuevos compuestos químicos
ECSP12011830A (es) Nuevos compuestos.
ECSP11011079A (es) Nuevos compuestos de hidroxiareno.
ECSP088905A (es) Nuevos compuestos
ECSP11010816A (es) Nuevos Compuestos
UY33817A (es) ?nuevas oxindolpirimidinas bencílicas?.
UY33890A (es) Nuevas azaindolilfenil sulfonamidas como inhibidores de serina/ treonina cinasa
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
ECSP11010930A (es) Nuevos compuestos químicos
UY31982A (es) Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
UY32494A (es) Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
ECSP13012448A (es) Nuevas aminopirazoloquinazolinas.
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
UY31138A1 (es) Derivados de indolinonas sustituidas, composiciones conteniendolos y aplicaciones
CO6470899A2 (es) 2,4-diaminopirimidinas para el tratamiento de enfermedades caracterizadas por proliferación celular excesiva o normal
UY29149A1 (es) Tiazolil-dihidro-indazoles
CO6290768A2 (es) Tiazolil-dihidro-indazoles
CO6460762A2 (es) 5-alquinil-piridinas
UY33181A (es) Derivados de oxazolopirimidina 2,5-sustituidos.
ECSP12012110A (es) 5-alquinil-pirimidinas
ECSP11011464A (es) Tia-triaza-ciclopentazulenos